Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori

Digestive Diseases and Sciences

Volumn 60, Issue 10, 2015, Pages 2901-2912

  Yazbek, Priscila Baptistella ^a   Trindade, Ariane Biolcati ^a   Chin, Chung Man ^a   dos Santos, Jean Leandro ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Gastric diseases; H. pylori eradication; H. pylori resistance; Helicobacter pylori; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; BISMUTH CITRATE; BISMUTH SALICYLATE; CIPROFLOXACIN; CLARITHROMYCIN; CURCUMIN; ESOMEPRAZOLE; HERBACEOUS AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MULTIVITAMIN; NATURAL PRODUCT; OMEPRAZOLE; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFABUTIN; RIFAXIMIN; SITAFLOXACIN; TETRACYCLINE; TINIDAZOLE; UNINDEXED DRUG; VACCINE; WARFARIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; CHRONIC GASTRITIS; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEPTIC ULCER; PRIORITY JOURNAL; REVIEW; STOMACH ADENOCARCINOMA; TREATMENT FAILURE; ADENOCARCINOMA; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MALE; PROGNOSIS; RISK ASSESSMENT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; PEPTIC ULCER; PROGNOSIS; PROTON PUMP INHIBITORS; RISK ASSESSMENT; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84942191196     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3712-y     Document Type: Review

References (124)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186.
2. Ayala G, Escobedo-Hinojosa WI, Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol. 2014;20:1450–1469.
3. Gustafson J, Welling D. “No acid, no ulcer”—100 years later: a review of the history of peptic ulcer disease. Am Coll Surg. 2010;210:110–116.
4. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275.
5. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA. 1995;272:65–69.
6. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20:1438–1449.
7. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014;59:1698–1709.
8. Hunt RH, Xiao SD, Megraud F, et al. World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299–304.
9. Alarcón T, Martínez-Gomez MJ, Urruzuno P. Helicobacter pylori in pediatrics. Helicobacter. 2013;18:52–57.
10. Lehours P, Yilmaz O. Epidemiology of Helicobacter pylori infection. Helicobacter. 2007;12:1–3.
11. Egan BJ, Katicic M, O’Connor HJ, O’Morain CA. Treatment of Helicobacter pylori. Helicobacter. 2007;12:31–37.
12. Gerrits MM, Van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6:699–709.
13. Boltin D, Ben-Zvi H, Perets TT, et al. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015;53:522–527.
14. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male US veterans. Clin Gastroenterol Hepatol. 2015;S1542–3565:00122–00126.
15. Pacifico L, Osborn JF, Bonci E, Romaggioli S, Baldini R, Chiesa C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol. 2014;20:673–683.
16. Kamiji MM, de Oliveira RB. Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2005;17:973–981.
17. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–490.
18. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006;7:956–960.
19. Maeda S, Mentis AF. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2007;1:10–14.
20. Kalali B, Mejías-Luque R, Javaheri A, Gerhard MH. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm. 2014;2014:426309.
21. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357.
22. Malfertheiner P, Megraud F, O’morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61:646–664.
23. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis. 2004;36:322–326.
24. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21:1419–1424.
25. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol. 2006;20:113–117.
26. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556–563.
27. O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18:58–65.
28. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535–541.
29. Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical first line and second line treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2013;63:1410–1415.
30. Mcnicholl AG, Marin AC, Molina-Infante J, et al. Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244–249.
31. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121–128.
32. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013;37:647–650.
33. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–905.e5.
34. Marin AC, Mcnicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843–861.
35. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941–947.
36. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol. 2014;20:1517–1528.
37. Di Caro S, Fini L, Daoud Y, et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol. 2012;18:5669–5678.
38. Gisbert JP, Molina-Infante J, Ac Marin, et al. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013;48:652–656.
39. Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131–138.
40. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420–426.
41. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821–825.
42. Morgan DR, Torres J, Sexton R, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578–586.
43. González Carro P, Pérez Roldán F, De Pedro Esteban A, et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol. 2007;22:60–63.
44. Fiorini G, Vakil N, Zullo A, et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2013;11:507–510.
45. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–221.
46. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion. 2006;73:129–135.
47. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24:195–200.
48. Yun SP, Seon HG, Ok CS, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–456.
49. Hunt Rh, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;2:299–304.
50. Tursi A, Picchio M, Elisei W. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis. 2012;21:133–138.
51. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis. 2003;35:232–236.
52. Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacin based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2012;56:1643–1645.
53. Hirata Y, Ohmae T, Yanai A, et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents. 2012;39:352–355.
54. Murakami K, Furuta T, Ando T, et al. Japan Gast Study Group. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48:1128–1135.
55. Alsahli M, Michetti P. Lactobacilli for the management of Helicobacter pylori. Nutrition. 2001;17:268–269.
56. Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;79:475–479.
57. Guruge JL, Falk PG, Lorenz RG, et al. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc Natl Acad Sci USA. 1998;95:3925–3930.
58. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterol. 2000;118:1072–1079.
59. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;2:105–110.
60. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79–87.
61. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2003;17:755–773.
62. Goldman CG, Barrado DA, Balcarce N, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;22:984–988.
63. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431–436.
64. Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9:707–716.
65. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE. 2014;9:e111030.
66. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:25–32.
67. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–1079.
68. Li S, Huang XL, Sui JZ, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173:153–161.
69. Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter. 2013;18:18–23.
70. Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol. 2014;20:699–705.
71. Malfertheiner P, Selgrad M, Wex T. Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers. Gastroenterology. 2012;142:S-184.
72. Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter. 2013;18:18–23.
73. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine. 2012;30:5310–5315.
74. Altman E, Chandan V, Harrison BA, et al. Regional Helicobacter Pylori Study Group. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an alpha-1,6-glucan chain. Vaccine. 2012;30:7332–7341.
75. Li Y, Jiang Y, Xi Y, et al. Identification and characterization of H-2d restricted CD4+ T cell epitopes on Lpp 20 of Helicobacter pylori. BMC Immunol. 2012;13:68.
76. Li HB, Zhang JY, He YF, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine. 2012;31:120–126.
77. Yanaka A. Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori infected gastric mucosae in mice and human subjects. Curr Pharm Des. 2011;17:1532–1540.
78. Cerella C, Dicato M, Jacob C, Diederich M. Chemical properties and mechanisms determining the anti-cancer action of garlic-derived organic sulfur compounds. Anti-Cancer Agents Med Chem. 2011;1:267–271.
79. Borkowska A, Knap N, Antosiewicz J. Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis. Nutr Cancer. 2013;65:711–717.
80. Schäfer G, Kaschula CH. The immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anti-Cancer Agents Med Chem. 2014;14:233–240.
81. Sivam GP, Lampe JW, Ulness B, Swanzy SR, Potter JD. Helicobacter pylori—in vitro susceptibility to garlic (Allium sativum) extract. Nutr Cancer. 1997;27:118–121.
82. Iimuro M, Shibata H, Kawamori T, et al. Suppressive effects of garlic extract on Helicobacter pylori-induced gastritis in Mongolian gerbils. Cancer Lett. 2002;187:61–68.
83. Graham DY, Anderson SY, Lang T. Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:1200–1202.
84. McNulty CA, Wilson MP, Havinga W, Johnston B, O’Gara EA, Maslin DJ. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori. Helicobacter. 2001;6:249–253.
85. You WC, Brown LM, Zhang L, et al. Randomized double blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–983.
86. Matsubara S, Shibata H, Ishikawa F, et al. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun. 2003;310:715–719.
87. Tombola F, Campello S, De Luca L, et al. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen Helicobacter pylori. FEBS Lett. 2003;543:184–189.
88. Stoicov C, Saffari R, Houghton J. Green tea inhibits Helicobacter growth in vivo and in vitro. Int J Antimicrob Agents. 2009;33:473–478.
89. Mabe K, Yamada M, Oguni I, Takahashi T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother. 1999;43:1788–1791.
90. Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F. Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food Res Int. 2011;44:964–969.
91. Asha MK, Debraj D, Prashanth D, et al. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol. 2013;145:581–586.
92. Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori properties of gut gard. Prev Nutr Food Sci. 2013;18:104–110.
93. Osato MS, Reddy SG, Graham DY. Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig Dis Sci. 1999;44:462–464.
94. McGovern DP, Abbas SZ, Vivian G, Dalton HR. Manuka honey against Helicobacter pylori. J R Soc Med. 1999;92:439.
95. Cui K, Lu W, Zhu L, Shen X, Huang J. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochem Biophys Res Commun. 2013;435:289–294.
96. Coelho LG, Bastos EM, Resende CC, et al. Brazilian green propolis on Helicobacter pylori infection. A pilot clinical study. Helicobacter. 2007;12:572–574.
97. Santos AM, Lopes T, Oleastro M, et al. Curcumin inhibits gastric inflammation induced by Helicobacter pylori infection in a mouse model. Nutrients. 2015;7:306–320.
98. De R, Kundu P, Swarnakar S, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother. 2009;53:1592–1597.
99. Aditi A, Graham DY. Vitamin C, gastritis and gastric disease: a historical review and update. Dig Dis Sci. 2012;57:2504–2515.
100. Sezikli M, Çetinkaya ZA, Güzelbulut F, et al. Effects of alpha tocopherol and ascorbic acid on Helicobacter pylori colonization and the severity of gastric inflammation. Helicobacter. 2012;17:127–132.
101. Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr. 2011;106:1632–1637.
102. Dekker KA, Inagaki T, Gootz TD, et al. CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities. J Antibiot. 1997;50:833–839.
103. Kanamaru T, Nakano Y, Toyoda Y, et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother. 2001;45:2455–2459.
104. Vecchione JJ, Sello JK. A novel tryptophanyl-tRNA synthetase gene confers high-level resistance to indolmycin. Antimicrob Agents Chemother. 2009;53:3972–3980.
105. Lee JH, Shim JS, Lee JS, et al. Inhibition of pathogenic bacterial adhesion by acidic polysaccharide from green tea (Camellia sinensis). J Agric Food Chem. 2006;54:8717–8723.
106. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol. 2009;125:218–223.
107. Lengsfeld C, Deters A, Faller G, Hensel A. High molecular weight polysaccharides from black currant seeds inhibit adhesion of Helicobacter pylori to human gastric mucosa. Planta Med. 2004;70:620–626.
108. Loke MF, Lui SY, Ng BL, Gong M, Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol. 2007;50:231–238.
109. 13C-urea breath test. Yakugaku Zasshi. 2012;132:601–607.
110. Lomas J, Anderson GM, Domnick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306–1311.
111. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5–12.
112. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS ONE. 2013;8:e62162.
113. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–528.
114. Rice PJ, Perry RJ, Afzal Z, Stockley IH. Antibacterial prescribing and warfarin: a review. Br Dent J. 2003;194:411–415.
115. Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32:486–490.
116. Sahai J, Healy DP, Stotka J, Polk RE. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302–304.
117. Lu ZK, Yuan J, Li M, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015;14:295–303.
118. Villamañán E, Armada E, Ruano M. Drug-induced QT interval prolongation: do we know the risks? Med Clin (Barc). 2015;144:269–274.
119. Ericsson CD, Feldman S, Pickering LK, Cleary TG. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247:2266–2267.
120. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930–935.
121. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013;19:8168–8180.
122. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastroint Liver Dis. 2010;19:409–414.
123. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic Resistance. Gut. 2009;59:1143–1153.
124. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.